Heparin Excretion in Intact and Hepatectomized Rats

Summary

Metabolism and kinetics of ³H-heparin were compared in intact and hepatectomized rats. Rats were divided into three groups: 1) intact rats with biliary fistulas and cystostomies 2) intact rats with only cystostomies and 3) hepatectomized rats with cystostomies. Radioactivity in blood, bile and urine besides anticoagulant activity in blood and urine were examined. In addition, column chromatography of urine was used to isolate possible metabolites. Seventy percent and 80% of the radioactive dose was found in the urine of intact rats at 24 hr and 48 hr. Close to 5% of the radioactivity was found in bile or rats with a biliary fistula after 48 hr. The APTT declined to near normal values at 1 hr whether rats had a biliary fistula or not. In contrast, only 25 % of the radioactivity could be excreted into the urine of hepatectomized rats in 24 hr; the APTT did not decline as fast and at 5 hr, it was still 100 seconds. Only one radioactive component could be isolated on chromatography from all urines of these animals and appears to be similar to the original heparin. Thus, the liver has an important role to play in regulating the anticoagulant effects and excretion of heparin.

Keywords

Heparin - Hepatectomy - APTT - Excretion

• References

• 1 Barrowcliffe TW, Johnson EA, Thomas D. Antithrombin III and heparin. Br Med Bull 1978; 34: 143-150
• 2 Chonelli JA. The relationship of molecular weight, and sulfate content and distribution to anticoagulant activity of heparin preparations. Carbohydrate Res 1974; 37: 145-154
• 3 Johnson EA, Mulloy B. The molecular weight range of mucosal heparin preparations. Carbohydrate Res 1967; 51: 119-127
• 4 Shanberge JN, Gruhl M, Kitani T, Ambegaonkar S, Kambayashi J, Nakagawa M, Lenter D. Fractionated tritium-labelled heparin studies in vitro and in vivo. Thromb Res 1978; 13: 767-783
• 5 Barrowcliffe TW, Johnson EA, Eggleton CA, Kemball-Cook G, Thomas DP. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haemat 1979; 41: 573-583
• 6 Lane DA, MacGregor IR, Michalski R, Kakkar VV. Anticoagulant activities of four unfractionated and fractionated heparins. Thromb Res 1978; 12: 257-271
• 7 Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims G EC. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583
• 8 Eiber HB, Danishefsky I, Borelli FJ. Physiological disposition of heparin. Proc Soc Exp Biol Med 1958; 98: 672-674
• 9 Danishefsky I, Eiber HB. Studies on the metabolism of heparin. Arch Biochem Biophys 1959; 85: 53-61
• 10 Dawes J, Pepper DS. Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-860
• 11 McAllister BM, Demis DJ. Heparin metabolism: isolation and characterization of uroheparin. Nature 1966; 212: 293-294
• 12 Alant O, Varga L, Antoni F, Karacsonyi S, Faller J. Metabolism and anticoagulant effect of ⁵¹Cr-labelled heparin. Acta Physiol Acad Scient Hung 1973; 43: 261-267
• 13 Losito R, Barlow G, Lemieux E. ³H-heparin and antithrombin III in the isolated liver perfusion. Thromb Res 1977; 10: 83-93
• 14 Bollman JL, van Hook EV. A simplified two stage hepatectomy in the rat. J Appl Physiol 1967; 24: 722-725
• 15 Ogren S, Lindahl U. Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma. J Biol Chem 1975; 250: 2690-2697
• 16 Monkhouse FC. Physiological fractors concerned with the removal of injected heparin from the circulating blood. Amer J Physiol 1954; 178: 223-228
• 17 Loomis TA. Distribution and excretion of heparin. Proc Soc Exp Biol Med 1961; 106: 490-493
• 18 Lemaire A, Picard J, Gardais A. Le catabolisme de l’héparine. Etude in vivo de la désulfatation de l’héparine chez le rat. C R Acad Sc Paris; 1967: 949-952
• 19 Jaques LB, Jaques CM. Disappearance of heparin activity with liver globulins and determination of heparinase. Thromb Diathes Haemorrh 1963; 10: 71-80
• 20 Levy L, Petracek FJ. Chemical and pharmacological studies on N-resulfated heparin. Proc Exp Biol Med 1962; 109: 901-905
• 21 Bjomsson TD, Levy G. Pharmacokinetics of heparin.I. Studies of dose dependence in rats. J Pharmacol Exp Ther 1979; 210: 237-242
• 22 Bjornsson TD, and Levy G. Pharmacokinetics of heparin. II. Studies of time dependence in rats. J Pharmacol Exp Ther 1979; 210: 243-246
• 23 Pepper DS, Dawes J. Preparation and application of ¹²⁵I-labelled heparin. Thromb Haemostas 1977; 38: 15
• 24 Schwarz EC, Usteri C, Koller F. Heparinresistenz und Heparinüberempfindlichkeit. Acta Haematol 1950; 4: 149-157
• 25 Teien AN. Heparin elimination in patients with liver cirrhosis. Thromb Haemostas 1977; 38: 701-706
• 26 Teien AN, Lie M. Heparin elimination in patients with various diseases. Thromb Haemostas 1977; 38: 85